KU Leuven
Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancer
2023
Leuven
Study lead by Massimiliano Mazzone: Among the features characterizing the tumor microenvironment (TME), metabolism-mediated immunosuppression is an important factor underlying treatment resistance in pancreatic cancer patients. As such, we will investigate the inhibition of a CDA/UDP/P2Y6 axis in the TME of pancreatic tumors, which we envision holds the potential to improve immunotherapy by breaking tumor-associated macrophage-mediated immunosuppression and sensitizing T cell activation to immune checkpoint blockade.